Company profile

Fresenius Medical Care AG

NYSE:FMSMisc Health and Biotechnology Services

Drug pipeline (7)

AssetStageRevenueTrialsStatus
Calcitriolapproved0
Calcium acetateapproved0
Calcium Chlorideapproved0
FERRIC OXYHYDROXIDEapproved0
MAGNESIUM CHLORIDEapproved0

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (41)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT00915369phase1unknown2009-03-012010-04-01Fresenius Kabi Oncology Ltd.A Clinical Trial to Study the Effects of Nanoparticle Based Paclitaxel Drug, Which Does Not Contain the Solvent Cremophor, in Advanced Breast Cancer
NCT04934072phase3completed2021-06-162023-08-07Fresenius Kabi SwissBioSim GmbHA Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis
NCT02795039phase1completed2016-06-012017-03-03Fresenius KabiBioequivalence Study of Fulvestrant Injection 50 mg/mL in Healthy Post-menopausal Female Subjects
NCT02086227phase1completed2013-05-012013-06-01Fresenius Kabi USA, LLCBioequivalence of Fresenius Kabi USA, LLC Glucagon for SC Injection Compared to Glucagon for Injection (Bedford Laboratories)
NCT03666546phase4completed2018-11-262019-03-05Fresenius KabiBlood Glucose Response After Oral Intake of Lactulose in Mildly Constipated Patients With Diabetes Mellitus Type 2

FDA applications (10)

ApplicationTypeApplicantProducts
ANDA 075766ANDAFRESENIUS MEDICAL CARE NORTH AMERICA
ANDA 078177ANDAFRESENIUS MEDICAL CARE NORTH AMERICA
NDA 018379NDAFRESENIUS MEDICAL CARE NORTH AMERICA
NDA 018883NDAFRESENIUS MEDICAL CARE NORTH AMERICA
NDA 019395NDAFRESENIUS MEDICAL CARE NORTH AMERICA